#For patients
Written for adults considering a peptide as part of their health management.
Oral incretin therapies for weight loss
Oral semaglutide and orforglipron bring GLP-1 based weight management into tablet form. Here is what the evidence does and does not show.
The trade-offs of widespread GLP-1 use
GLP-1 medicines have strong trial evidence, but widespread use also raises questions about access, marketing, and evidence beyond the headlines.
GLP-1 injection site reactions explained
Tirzepatide, semaglutide and other GLP-1 drugs cause injection site and skin reactions in about a third of reported adverse events, an FDA data review finds.
GLP-1 skin reactions: what FAERS shows
A 2026 Clinics in Dermatology FAERS review maps injection site reactions, alopecia, urticaria, and rarer skin events in GLP-1 receptor agonist users.
GLP-1 Drugs in Children Ages 8-11: Trends
A 3.5-million-child Pediatrics study found GLP-1 prescriptions for 8-to-11-year-olds grew 310-fold from 2019 to 2026, all off-label.
Is CJC-1295/ipamorelin flushing normal?
Facial flushing after CJC-1295 and ipamorelin injections is a known, documented reaction pattern for this peptide class, not an unusual one.
What is KLOW? The peptide blend, explained
KLOW mixes BPC-157, TB-500, GHK-Cu, and KPV. Here is what the evidence for each ingredient shows, and why none of it answers a fracture-healing question.
PT-141 for low libido on GLP-1 drugs
Reduced libido is a reported side effect on GLP-1 drugs. Here is what the evidence shows for PT-141 (bremelanotide) and kisspeptin as options for women.
Retatrutide and DKA in type 1 diabetes
A Cureus 2026 case report: a type 1 diabetes patient self-injected online-sourced retatrutide and developed impending DKA alongside a Shigella infection.
Needle reuse and vial contamination
A used needle can carry material into another vial. CDC injection-safety guidance explains why each vial entry needs new sterile equipment.
GLP-1 Drugs and Hair Loss: Cohort Evidence
A 2026 cohort study found semaglutide and tirzepatide carry higher alopecia odds than other GLP-1 drugs, with rapid weight loss as the likely driver.
Tirzepatide weight loss outcomes in PCOS
A UK real-world study found similar 10-month tirzepatide weight loss in women with self-reported PCOS and women without PCOS.